Atlas Trials

A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia (ITP)

Clinical trial NCT06094881 · RECRUITING

Trial details

NCT number
NCT06094881
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Immune ThrombocytopeniaTreatment
Start date
2023-12-01
Primary completion
2025-11-01
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.